{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:17:13Z","timestamp":1765232233186},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T00:00:00Z","timestamp":1424995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40265-015-0362-5","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T12:53:27Z","timestamp":1424955207000},"page":"515-524","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Daclatasvir: A Review of Its Use in Adult Patients with Chronic Hepatitis C Virus Infection"],"prefix":"10.1007","volume":"75","author":[{"given":"Paul L.","family":"McCormack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,27]]},"reference":[{"issue":"2","key":"362_CR1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"European Association for the Study of the Liver","year":"2014","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420.","journal-title":"J Hepatol."},{"key":"362_CR2","unstructured":"World Health Organization. Hepatitis C: fact sheet no. 164. 2014. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/# . Accessed 10 Feb 2015."},{"key":"362_CR3","doi-asserted-by":"crossref","unstructured":"Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2014. doi: 10.1002\/hep.27259 .","DOI":"10.1002\/hep.27259"},{"issue":"11","key":"362_CR4","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jmv.23399","volume":"84","author":"MM Manos","year":"2012","unstructured":"Manos MM, Shvachko VA, Murphy RC, et al. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol. 2012;84(11):1744\u201350.","journal-title":"J Med Virol."},{"issue":"7262","key":"362_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399\u2013401.","journal-title":"Nature."},{"issue":"7265","key":"362_CR6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798\u2013801.","journal-title":"Nature."},{"issue":"2","key":"362_CR7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","volume":"61","author":"European Association for the Study of the Liver","year":"2014","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61(2):373\u201395.","journal-title":"J Hepatol."},{"key":"362_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1743-422X-8-161","volume":"8","author":"UA Ashfaq","year":"2011","unstructured":"Ashfaq UA, Javed T, Rehman S, et al. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:161.","journal-title":"Virol J."},{"key":"362_CR9","unstructured":"European Medicines Agency. Sovaldi (sofosbuvir): summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002798\/WC500160597.pdf . Accessed 10 Feb 2015."},{"key":"362_CR10","unstructured":"European Medicines Agency. Olysio (simeprevir): summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002777\/WC500167867.pdf . Accessed 10 Feb 2015."},{"key":"362_CR11","unstructured":"US FDA. Olysio (simeprevir) capsules: US prescribing information. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205123s002lbledt.pdf . Accessed 10 Feb 2015."},{"key":"362_CR12","unstructured":"US FDA. Sovaldi (sofosbuvir) tablets: US prescribing information. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204671s001lbl.pdf . Accessed 10 Feb 2015."},{"key":"362_CR13","doi-asserted-by":"crossref","unstructured":"Druyts E, Lorenzi M, Toor K, et al. Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. Q J Med. 2014. doi: 10.1093\/qjmed\/hcu202 .","DOI":"10.1093\/qjmed\/hcu202"},{"key":"362_CR14","unstructured":"European Medicines Agency. Daklinza (daclatasvir dihydrochloride): summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf . Accessed 10 Feb 2015."},{"key":"362_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96\u2013100.","journal-title":"Nature."},{"issue":"10","key":"362_CR16","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","volume":"110","author":"J Guedj","year":"2013","unstructured":"Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA. 2013;110(10):3991\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"key":"362_CR17","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/AAC.01209-12","volume":"56","author":"LA Pelosi","year":"2012","unstructured":"Pelosi LA, Voss S, Liu M. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother. 2012;56:5230\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"362_CR18","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54(9):3641\u201350.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"362_CR19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","volume":"54","author":"RA Fridell","year":"2011","unstructured":"Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54(6):1924\u201335.","journal-title":"Hepatology."},{"issue":"9","key":"362_CR20","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","volume":"58","author":"C Wang","year":"2014","unstructured":"Wang C, Jia L, O\u2019Boyle DR 2nd, et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother. 2014;58(9):5155\u201363.","journal-title":"Antimicrob Agents Chemother."},{"key":"362_CR21","doi-asserted-by":"crossref","unstructured":"Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015. doi: 10.1002\/hep.27726 .","DOI":"10.1002\/hep.27726"},{"key":"362_CR22","author":"C H\u00e9zode","year":"2014","unstructured":"H\u00e9zode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2014. doi: 10.1136\/gutjnl-2014-307498 .","journal-title":"Gut"},{"issue":"Suppl S2","key":"362_CR23","first-page":"7","volume":"21","author":"I Jacobson","year":"2014","unstructured":"Jacobson I, Zeuzem S, Flisiak R. Daclatasvir vs telaprevir in combination with peginterferon alfa\/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results [abstract no. 0213]. J Viral Hepat. 2014;21(Suppl S2):7\u20138.","journal-title":"J Viral Hepat"},{"key":"362_CR24","doi-asserted-by":"crossref","unstructured":"H\u00e9zode C, Alric L, Brown A, et al. Daclatasvir in combination with peginterferon alfa-2a and ribavirin for treatment-naive patients with HCV genotype 4 infection: phase 3 COMMAND-4 results [abstract no. 819 plus poster]. In: IDWeek. 2014.","DOI":"10.1093\/ofid\/ofu052.527"},{"key":"362_CR25","doi-asserted-by":"crossref","unstructured":"McPhee F, Hernandez D, Zhou N, et al. Virologic escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther. 2014. doi: 10.3851\/imp2729 .","DOI":"10.3851\/IMP2729"},{"issue":"3","key":"362_CR26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321.","journal-title":"N Engl J Med."},{"issue":"9","key":"362_CR27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","volume":"12","author":"S Pol","year":"2012","unstructured":"Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. 2012;12(9):671\u20137.","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"362_CR28","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","volume":"54","author":"RE Nettles","year":"2011","unstructured":"Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011;54(6):1956\u201365.","journal-title":"Hepatology."},{"issue":"8","key":"362_CR29","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1128\/AAC.02724-14","volume":"58","author":"T Furihata","year":"2014","unstructured":"Furihata T, Matsumoto S, Fu Z, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014;58(8):4555\u201364.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"362_CR30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","volume":"18","author":"M Bifano","year":"2013","unstructured":"Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18(7):931\u201340.","journal-title":"Antivir Ther."},{"issue":"5","key":"362_CR31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3851\/IMP2731","volume":"19","author":"N Izumi","year":"2014","unstructured":"Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther. 2014;19(5):501\u201310.","journal-title":"Antivir Ther."},{"issue":"Suppl 2","key":"362_CR32","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/S0168-8278(12)61219-7","volume":"56","author":"V Ratziu","year":"2012","unstructured":"Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of phase 2b COMMAND-2 trial [abstract no. 1207, plus poster presented at the 47th Annual Meeting of the European Association for the Study of the Liver, 18\u201322 Apr 2012, Barcelona]. J Hepatol. 2012;56(Suppl 2):S478\u20139.","journal-title":"J Hepatol."},{"issue":"5","key":"362_CR33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3851\/IMP2730","volume":"19","author":"F Suzuki","year":"2014","unstructured":"Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther. 2014;19(5):491\u20139.","journal-title":"Antivir Ther."},{"key":"362_CR34","doi-asserted-by":"crossref","unstructured":"Dore GJ, Lawitz E, H\u00e9zode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015;148(2):355\u201366.e1.","DOI":"10.1053\/j.gastro.2014.10.007"},{"key":"362_CR35","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2015. http:\/\/clinicaltrials.gov\/ . Accessed 10 Feb 2015."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0362-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0362-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0362-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T08:52:11Z","timestamp":1566377531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0362-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,27]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0362-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,27]]}}}